Acute GvHD therapy / ImStem Biotech - LARVOL DELTA

Small Extracellular Vesicles Derived From Mesenchymal Stem Cells Exert Neuroprotective Effect Against a Model of Dopamine Dysfunction by Inhibiting Caspase-8/Caspase-3-Mediated Apoptosis. (PubMed, J Integr Neurosci) - "The results suggest that T-MSCs-sEVs represent a promising biological candidate for future therapeutic strategies aimed at treating PD."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease • CASP3 • CASP8 • CLU

A Comparative Study of Mesenchymal Stem Cell Derived From Human Embryonic Stem Cell-derived Mesenchymal Stem Cells Through a Trophoblast-like Stage and Bone Marrow-derived Mesenchymal Stem Cells in Treating Acute Xenogeneic Graft-versus-host Disease in Humanized Mice. (PubMed, Transplantation) - "Both T-MSCs and BM-MSCs can prevent CD4+ and CD8+ T-cell proliferation, possibly by facilitating prostaglandin E2 release and promoting the proliferation of CD3+CD25high+Foxp3+ T cells, thereby alleviating the development of aGvHD. T-MSCs and BM-MSCs may serve as promising candidates for treating aGvHD in the clinical setting."

Journal • Preclinical • Acute Graft versus Host Disease • Graft versus Host Disease • Immunology • CD4 • CD8 • FOXP3 • IDO1 • PD-L1 • PRKDC

Accurate Delivery of Mesenchymal Stem Cell Spheroids With Platelet-Rich Fibrin Shield: Enhancing Survival and Repair Functions of Sp-MSCs in Diabetic Wound Healing. (PubMed, Adv Sci (Weinh)) - "Results show that this combination significantly promotes wound repair and regulates the immune microenvironment. The study suggests that PRF is a promising bio-derived scaffold for stem cell applications in diabetic wounds, offering new directions for stem cell therapy and biomimetic scaffold material development."

Journal

miR-100a-5p-enriched exosomes derived from mesenchymal stem cells enhance the anti-oxidant effect in a Parkinson's disease model via regulation of Nox4/ROS/Nrf2 signaling. (PubMed, J Transl Med) - "The study suggests that miR-100-5p-enriched T-MSCs-Exo may be a promising biological agent for the treatment of PD. Schematic summary of the mechanism underlying the neuroprotective actions of T-MSCs-Exo in PD. T-MSCs Exo may inhibit the expression level of the target gene NOX4 by delivering miR-100-5p, thereby reducing ROS production and alleviating oxidative stress via the Nox4-ROS-Nrf2 axis, thus improving DA neuron damage in PD."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease • MIR100 • NOX4